Research
Hormonal
Gestational diabetes is associated with increased risks of perinatal complications including hypertensive disorders, preterm delivery, shoulder dystocia, stillbirth, neonatal hypoglycemia, and cesarean delivery.
GDM increases the risk of several serious complications for both mother and baby, including high blood pressure, early delivery, difficult birth, and low blood sugar in the newborn. Proper management is crucial to mitigate these risks.
StrongSupportsVERY_HIGH confidence
Perinatal complications associated with GDM include hypertensive disorders, preterm delivery, shoulder dystocia, stillbirths, clinical neonatal hypoglycemia, hyperbilirubinemia, and cesarean deliveries.
Why this rating
Supported by large prospective cohort studies (HAPO) and randomized trials (ACHOIS, MiG).
Source
Gestational diabetes: risks, management, and treatment options
Catherine Kim · International Journal of Women s Health · 2010
DOI 10.2147/ijwh.s13333
narrative_reviewCited 197×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin therapy is the recommended pharmacological intervention for GDM when medical nutrition therapy and physical activity fail to achieve glycemic goals.Strong
- Medical nutrition therapy involving moderate caloric restriction (1600-1800 kcal/day) and physical activity is the primary management strategy for gestational diabetes, aiming to maintain normoglycemia and appropriate fetal growth without inducing ketosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →